Leveraging artificial intelligence, the Rho software assessment of X-rays may allow earlier detection of bone loss.
The Food and Drug Administration (FDA) has granted a De Novo classification to Rho™, an artificial intelligence (AI) software that may facilitate bone loss detection through opportunistic screening of X-rays for low bone mineral density (BMD).
Noting that less pronounced bone loss is more difficult for radiologists to assess via standard X-rays, 16 Bit, the manufacturer of the Rho software, said adjunctive use of Rho can be a viable alternative. Offering automated scans of a variety of X-rays, ranging from frontal chest projections and lumbar spine views to X-rays of the pelvis and knee, Rho provides alerts of possible low BMD, according to 16 Bit.
In a recently published study in the Journal of the American College of Radiology (JACR), researchers found that Rho demonstrated area under the receiver operating characteristic (AUROC) curves of 89 percent, 87 percent and 82 percent in three independent data sets for detecting low BMD.
“An opportunistic screening tool such as this opens a window for early prevention and intervention strategies to slow the rate of bone loss,” noted lead study author Alexander Bilbily, M.D., FRCPC, the co-founder and co-CEO of 16 Bit, and an assistant professor and director of the Augmented Precision Medicine Lab at Sunnybrook Health Sciences Centre in Toronto, and colleagues.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.